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Abstract
Several markers identify cancer stem cell-like populations, but little is known about the functional roles of stem cell surface
receptors in tumor progression. Here, we show that the endothelial protein C receptor (EPCR), a stem cell marker in
hematopoietic, neuronal and epithelial cells, is crucial for breast cancer growth in the orthotopic microenvironment of the
mammary gland. Mice with a hypomorphic allele of EPCR show reduced tumor growth in the PyMT-model of spontaneous
breast cancer development and deletion of EPCR in established PyMT tumor cells significantly attenuates transplanted
tumor take and growth. We find expansion of EPCR+ cancer stem cell-like populations in aggressive, mammary fat pad-
enhanced human triple negative breast cancer cells. In this model, EPCR-expressing cells have markedly increased
mammosphere- and tumor-cell initiating activity compared to another stable progenitor-like subpopulation present at
comparable frequency. We show that receptor blocking antibodies to EPCR specifically attenuate in vivo tumor growth
initiated by either EPCR+ cells or the heterogenous mixture of EPCR+ and EPCR- cells. Furthermore, we have identified tumor
associated macrophages as a major source for recognized ligands of EPCR, suggesting a novel mechanism by which cancer
stem cell-like populations are regulated by innate immune cells in the tumor microenvironment.
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Introduction
The coagulation cascade is an evolutionary conserved pathway
in vertebrates that maintains vascular integrity, protects from
infection, and supports regenerative processes after injury.
Coagulation is initiated through the intrinsic pathway by
polyanionic intrinsic or extrinsic danger signals [1,2] or through
the extrinsic pathway by the cytokine receptor family member
tissue factor (TF) that is expressed by vessel wall and innate
immune cells [3]. TF binds the serine protease coagulation factor
(F) VIIa and the TF-FVIIa complex activates FX to FXa, leading
to thrombin generation, fibrin formation and platelet activation
that are crucial for hemostatic clot formation and prevention of
bleeding. The TF-VIIa complex also regulates angiogenesis
through coagulation-independent cell signaling [4] and thereby
supports coagulation-dependent mechanisms in wound repair [5].
Activation of the coagulation system is also a characteristic of
advanced cancer and thrombotic complications are major
contributors to morbidity and mortality in cancer patients [6].
Oncogenic transformations induce TF expression by a variety of
cancer types and TF promotes the prothrombotic state of cancer
patients and thrombin-dependent activation of the host hemostatic
system in metastasis [5]. In addition, TF-FVIIa regulates cancer
cell migration and initiates proangiogenic cell signaling by
proteolytic cleavage and activation of the G protein-coupled
protease activated receptor (PAR) 2, supporting tumor develop-
ment and growth in orthotopic tumor microenvironments [7–11].
Other procoagulant proteases, i.e. thrombin and FXa, as well as
matrix metalloproteases have pleiotropic pro-invasive and growth
promoting effects on tumor cells and these effects are frequently
dependent on activation of the thrombin receptor PAR1 [12,13].
The procoagulant effects of the TF pathway are counterbal-
anced by the protein C (PC) anticoagulant pathway to avoid
intravascular thrombosis [14]. PC is activated when thrombin
binds to endothelial cell-expressed thrombomodulin. In this
pathway, a CD1d–like immune receptor, the endothelial protein
C receptor (EPCR), binds the c-carboxyl glutamic acid-rich (Gla)
domain of PC and thereby markedly improves PC activation at
the endothelial interface. EPCR also serves as the co-receptor for
activated PC (aPC) in vascular protective signaling mediated by
activation of PAR1 [15–17]. Endothelial overexpression of EPCR
attenuates metastasis, presumably by dampening thrombin gen-
eration that supports metastatic tumor cell survival in vascular
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e61071
niches [18]. EPCR-dependent PAR1 activation by aPC also
stimulates cell migration of breast cancer cells or prevents
apoptosis of lung cancer cells to enhance metastasis [19,20]. In
addition to aPC, EPCR binds the amino-terminal Gla-domains of
FVIIa and FXa and contributes to signaling by these proteases
[21,22], but contributions of these receptor interactions to cancer
progression are unknown.
In addition, EPCR is found on hematopoietic, neuronal and
epithelial progenitor populations [23–26], but functional roles of
EPCR in stem cell biology are incompletely understood. EPCR is
expressed by highly aggressive basal-like breast cancer subtypes
[27]. Clinical cancers contain stem cell-like subpopulations that
can be selected by several markers, including a CD44high/CD242
surface phenotype [28], expression of aldehyde dehydrogenase
(ALDH1) [29], as well as EPCR [30]. However, normal stem cell
niches and solid tumors contain multiple stem cell populations that
are not organized in a strict hierarchy, but rather bi-directionally
interconvert between themselves in the context of cues from their
environment [31] and also with non-stem cell compartments, in
particular in breast cancer [32].
Large scale genomic data, while supporting a link between the
expression of stem cell markers and poor prognosis, have also
illustrated the challenges to identify clinically relevant cancer stem
cell properties in the context of tumor heterogeneity and plasticity
[33]. New insights into the biology of cancer stem cell-like
populations can be expected from the identification of pathways
that are relevant for the maintenance or expansion of these
subpopulations in tumor microenvironments. Initial evidence in
glioblastoma indicates that stem cell markers, such as the integrin
a6, are indeed critical for tumor progression [34]. While EPCR-
selected populations of breast cancer cells grow as non-adherent
spheroids and have high tumorigenicity when injected at low cell
numbers [35], functional roles of this marker remained elusive.
Here, we provide combined genetic and pharmacological evidence
that EPCR functions as a crucial regulator and not solely as a
surface tag of tumor-initiating, cancer stem cell-like populations in
vivo.
Materials and Methods
Ethics Statement
All experiments were performed under protocols approved by
the Scripps Institutional Animal Care and Use Committee in
accordance with United States Public Health Policy regarding the
care and use of laboratory animals. All tumor growth experiments
were monitored at least twice weekly by measurements of tumor
sizes. For transplanted tumor growth experiments, all groups were
euthanized by overdose inhalation anesthesia when one of the
animals had reached the maximally allowed tumor size of 1.5 cm.
For cohorts of mice with spontaneous, multifocal breast cancer
development, individual mice were euthanized when one of the
tumors reached the allowed tumor size of 1.5 cm.
Tumor models
CB17/SCID and C57BL/6J mice were from Jackson Labora-
tory or the Scripps rodent breeding colony. PyMT-C57BL/6 mice
[36,37] were crossed with EPCRLow/Low mice [38]. The mice with
mutated EPCR alleles were generated by targeting 129-derived ES
cells and extensively back-crossed with C57BL/6. Because of the
close proximity of the EPCR and the agouti locus, these mice
retained a brown fur color. In order to control for this difference
from wild-type C57BL/6 mice, we compared EPCRLow/Low mice
with littermate-derived EPCRLow/WT mice. Heterozygous PyMT-
EPCRLow/WT displayed tumor progression and sizes indistinguish-
able from PyMT-C57BL/6 mice housed and monitored at the
same time in our animal facility (Fig. S1A). Cohorts of PyMT-
EPCRLow/Low mice and PyMT-EPCRLow/WT controls were
followed for spontaneous tumor progression, as described [7,37].
Tumor architecture was analyzed by Hematoxylin and Eosin
staining (H&E). Tumor vessel density and size as well as
macrophage counts were determined by IMARIS 64 (BitPlane
Inc) by quantifying at least 3 fields per tumor. As in our previous
experiments [7,8], cells were injected into the 2nd thoracic
mammary gland for transplanted tumor growth studies. To
generate EPCR-deficient PyMT-cells, EPCRflox/flox mice exten-
sively backcrossed with C57BL/6 mice [39] were crossed with
PyMT-C57BL/6 mice. Tumor cells were isolated by outgrowth
from minced tumors in L15 with 10% FCS and insulin (1 mg/ml).
PyMT-EPCRflox/flox cells were transduced twice on consecutive
days with 1000 ppc Ad5 cre recombinase or control virus. EPCR-
deletion was confirmed by Western blotting [21] and cells were
injected into the mammary fat pad for tumor growth monitoring.
For xenograft tumor growth experiments, 16106 unsorted
human MDA-MB-231 mfp cells [40] were harvested with trypsin
and injected in serum-free medium into the 2nd thoracic
mammary gland of CB17/SCID mice [8]. For tumor-take
experiments, MDA-MB-231 mfp cells were stained with aTF
(10H10-Alexa 647) and aEPCR (CD201-PE RCR252, BD
Pharmingen) for FACS to isolate EPCR+ and EPCR2 subpopu-
lations. For comparison of tumor take and growth of EPCR+ and
EPCR2 subpopulations, isolated cells in 50 ml growth factor-
reduced matrigel cells were placed bilaterally in the same animals.
For FACS analysis, tumors were digested in DMEM with 2 mg/
ml collagenase A (Roche), 10 ml DNase I (New England Biolab)
with agitation at 37uC for 40 minutes. After FCS quenching and
passage through a 70 mm cell strainer, tumor cells were isolated
with human integrin b1 specific antibody (AIIB2, University of
Iowa Developmental Studies Hybridoma Bank) and viable cells
identified by AAD (Life Technologies) were analyzed for
expression of TF and EPCR by FACS.
Microarray analysis
MDA-MB-231 mfp subpopulations were FACS isolated, im-
mediately preserved in RLT buffer (Qiagen) with 10% b-
mercapto-ethanol, and mRNA extracted for profiling on Affyme-
trix HG-U219 chips. Data was normalized with the Robust
Multichip Average method in the statistical software package, R
(version 2.14.2). Microarray probes were summarized with a
custom chip description file based on Entrez Gene identifiers
(version 15.0.0) obtained from: http://brainarray.mbni.med.
umich.edu. Statistical analysis of differential gene expression was
performed with the Limma Bioconductor package. Because the
experimental design did not include any technical replicates, a
statistical evaluation required selection of two adjacent passages to
serve as a replicate pair. Samples from passages 22 and 23 were
selected for this purpose as their expression values were most
similar based on the principle component analysis, hierarchical
clustering, and pairwise expression plots. To identify genes
differentially expressed between EPCR+ and EPCR2 cells, the
remaining passages were treated as discrete points in a Limma
linear model of the data. Resulting FDR-corrected F-test p-values
of 0.01 and fold changes of 2-fold (log2 ratio = 1) were used to
select genes of interest. The moderated F-statistic tests if a given
gene is differentially expressed between populations in any of the
passages. The selected transcripts were further subjected to
hierarchical clustering and subgroups were analyzed for pathway
enrichment with Ingenuity Pathway Analysis (IngenuityH Systems,
www.ingenuity.com).
EPCR in Cancer Stem Cells
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In vitro assays
Mammospheres were grown on low attachment tissue culture
plates in DMEM/F12 supplemented with B27 (Invitrogen),
20 ng/ml FGF and 20 ng/ml EGF. Mammospheres were
quantified by cell counts. To measure proliferation of adherent
cells, cells were seeded at defined densities on untreated dishes or
culture plates coated with 5 mg/ml of the integrin a4 specific
ligand fibronectin fragment CS-1 (kindly provided by Dr. M. H.
Ginsberg), or 1:2-diluted serum-free supernatant from 805 G cells
that secrete extracellular matrix enriched in laminin 5. Antibodies
were added at a concentration of 100 mg/ml and replenished at
the same dose for incubations exceeding 48 hours, as indicated for
the specific experiments. Viable cells were quantified 24–72 hours
after seeding by MTT assay to assess proliferation and survival.
For FACS staining cells were harvested and stained with aTF
(10H10 alexa 647), aEPCR (CD201-PE RCR252, BD Pharmin-
gen), aCD49d (9F10 PE-Cy7, BioLegend), aCD104-biotin (439–
98, eBioscience) and streptavidin-Alexa 488 (Molecular Probes) or
control IgG1 for 30 minutes on ice. Cells were then washed and
analyzed on Aria II cytometer (BD Pharmingen). EPCR positive
cells were gated against a non-specific fluorescent channel.
For confocal microscopy, cells on glass coverslips were fixed
with 1% formaldehyde and stained with antibodies to TF (10H10-
FITC) and EPCR (CD201-PE, Pharmingen). After counterstain-
ing of nuclei with DAPI in PBS, 0.1% Triton 6100, cells were
mounted in fluorescent medium (Dako) and analyzed with a Zeiss
710 confocal microscope (objective 406PlanNeoFluor-1.3na) and
image collection with Zen 2009 software.
Gene expression analysis in the tumor microenvironment
Tumors from PyMT mice were digested as above and
macrophages were selected in PBS, 0.5% BSA, 2 mM EDTA,
pH 7.2 with either aCD11b or aCD11c paramagnetic beads at
4uC for 15 minutes and separated on LS columns (Miltenyi). Flow-
through and eluted fractions were extracted with TRIzol (Life
Technologies), further purified by RNeasy Mini Kit columns
(QIAGEN), followed by cDNA synthesis with SuperScript III (Life
Technologies). Transcript levels were quantified by Real Time
PCR using SyBr Green Master Mix (Applied Biosystems) on an
Applied Biosystems 7300 System and normalization against b
actin with primer pairs shown in Table S3.
Statistical analysis
Data are presented as mean6SD, unless otherwise stated. We
used Prism 5 for unpaired T-test or ANOVA with Bonferroni
posttest. Survival curves were analyzed by log rank test. Tumor
size differences in PyMT cohorts were analyzed by Mann-
Whitney, because the groups were not normally distributed.
Two-tailed two-way ANOVA and logistic regression models were
used to compare tumor volumes, weights and take between sorted
EPCR+ and EPCR2 cells using R version 2.15.0 (http://www.R-
project.org/) with p= 0.05.
Results
EPCR-expression defines a distinct subpopulation in
mammary fat pad-enhanced MDA-MB-231 mfp cells
Passage through the mammary fat pad can be employed to
select more aggressive tumor cell populations for tumor trans-
plantation studies. A mammary fat pad-enhanced derivative of the
triple negative breast cancer cell line MDA-MB-231 (MDA-MB-
231 mfp) with markedly improved tumor growth properties was
previously characterized [40] and used to study contributions of
TF-FVIIa-PAR2 coagulation protease signaling pathways to
tumor progression [8]. Our more recent data showed that the
stem cell receptor EPCR is required for signaling of another TF
protease complex, i.e. TF-FVIIa-FXa in which FXa cleaves PAR2
or PAR1 [21,41]. In order to begin to evaluate potential
contributions of EPCR to TF signaling in cancer progression,
we determined the co-expression of TF and EPCR by FACS.
Tumor initiating populations are enriched in the CD44high/
CD24low population of breast cancer isolates [28] and MDA-MB-
231 mfp cells were predominantly of this phenotype (Fig. 1A, left
panel). Surprisingly, double staining for EPCR and TF revealed
two distinct subpopulations, EPCR+ cells and cells with high TF
expression that were negative for EPCR (Fig. 1A, right panel). The
differential receptor expression was also demonstrated on adherent
cells, excluding artificial receptor release during cell detachment
(Fig. 1B).
These subpopulations could be reproducibly isolated by FACS
employing double staining and the depicted gates, yielding
EPCR+/TFlow and EPCR2/TFhigh cells. Western blotting of
sorted cells confirmed the differential expression of these two
receptors, excluding intracellular pools that escaped detection by
surface staining (Fig. 1C). In order to determine whether
expression of TF or EPCR was associated with a stable phenotype
of subpopulations or merely a fluctuation of receptor expression of
an otherwise genetically similar total population, we molecularly
characterized by microarray mRNA profiling sorted EPCR+ and
EPCR2 subpopulations from 6 consecutive passages. EPCR+ and
EPCR2 subpopulations were remarkably stable in the levels of
2642 differentially expressed transcripts (Fig. 1D, Table S1),
consistent with recent large scale genomic analysis demonstrating
a phenotypic equilibrium of metastable subpopulations in cancer
cell lines in culture [42].
Ingenuity pathway analysis of individual branches of the
depicted hierarchical clustering showed that genes upregulated
in EPCR2/TFhigh cells (red in Fig. 1D) were related to pathways
of TF and cancer progression, pro-angiogenic cytokine induction,
integrins and cytoskeletal function (Table S2A). The EPCR2 cells
not only expressed higher levels of TF mRNA, but also of TF’s
signaling receptor PAR2. These results were in accord with the
previously demonstrated TF-PAR2 mediated IL-8 proangiogenic
signaling and reciprocal regulation of TF and integrins [8,11,43].
Considering the previously demonstrated expression of EPCR
by stem cell populations, we focused our attention on the
differential abundance of stem cell markers between these
subpopulations. The gene clusters upregulated in EPCR+ cells
(blue in Fig. 1D) documented expression of markers associated
with an aggressive or stem cell-like phenotype, including
ALDH1B1 and ALDH1A3 [29], the hematopoietic stem cell
marker integrin a4 [44], and the pan stem cell maker integrin a6
[45]. However, EPCR+ cells did not clearly match the signatures
extracted for embryonic stem cells [46] and for EMT [47], or the
core stem cell signature of triple negative, basal-type breast cancer
[46] (Table S2B, C). Indeed, transcription factors of the core
signature were found to be significantly higher in either EPCR+
(TEAD4, MYBL2) or EPCR2 (HMGA1, HMGB1, KLF5,
NFE2L3) cells, indicating that EPCR+ and EPCR2 cells are
coexisting and relatively stable subpopulations expressing specific
subsets of stem cell and EMT markers in vitro.
EPCR deficiency attenuates spontaneous breast cancer
growth in the PyMT model
The segregation of EPCR and TF-PAR2 expression on
subpopulation of human breast cancer cells raised the question
whether EPCR made a contribution to tumor growth that was
distinct and independent of the established pro-angiogenic effect of
EPCR in Cancer Stem Cells
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TF signaling in breast cancer development [7,8,37]. We first
employed the oncogene-driven polyoma middle T (PyMT) model
that mimics important aspects of human breast cancer develop-
ment, which is dependent on both tumor cell-intrinsic signaling
pathways as well as tumor-host cell interactions [48], and has been
suitable to define the role of TF-PAR2 signaling in tumor
progression [7,10,37]. We crossed EPCR hypomorphic (EPCR-
Low/Low) mice [38] with PyMT mice to study spontaneous tumor
development in the presence of only very low levels of EPCR.
Cohorts of PyMT-EPCRLow/Low or heterozygous PyMT-EPCR-
Low/WT control mice developed palpable tumors indistinguishably
at an average age of 8 or 9 weeks, respectively (Fig. 2A, top panel).
The time to tumor appearance, a reflection of tumor progression
from the adenoma to carcinoma stage [48], was similar to
previously characterized cohorts of PyMT-C57BL/6 mice [7,37].
However, PyMT-EPCRLow/Low mice had significantly reduced
overall tumor burden compared to controls (Fig. 2A, middle panel)
and consequently survived longer (24.5 versus 22 weeks, respec-
tively) until institutional tumor size limits required euthanasia
(Fig. 2A, bottom panel). Overexpression of EPCR in endothelial
Figure 1. Analysis of MDA-MB-231 mfp cells sorted based on EPCR expression. A Cells were double stained for CD44 and CD24, or EPCR
and TF using directly labeled antibodies and analyzed by FACS. B Non-permeabilized cells were stained for EPCR and TF, confirming the presence of
EPCR+/TFlow and EPCR2/TFhigh subpopulations in adherent MDA-MB-231 mfp cells; two examples of stained unsorted populations are shown (scale
bar 15 mm). C Western blotting of sorted MDA-MB-231 mfp cells confirmed the EPCR+/TFlow and EPCR2/TFhigh phenotypes, respectively, and
excluded intracellular pools of EPCR in EPCR2 cells. A representative blot and quantification of EPCR and TF levels in cells from 4 independent sorts
are shown (*** p,0.001, ** p,0.005, T-test; mean6SD). D EPCR+ and EPCR2 populations were isolated in 6 consecutive FACS sorts and profiled for
mRNA expression. The sorts of passage 22 and 23 cells were treated as replicates in the data analysis and the clustering for the mean value for these
samples and 4 additional earlier and later sorts is shown. Hierarchical Clustering Subbranches: The dendrogram was cut at a defined height to yield 10
gene clusters. Of these, 6 had transcripts upregulated in EPCR+ cells (Branch 1–6) and 4 had transcripts upregulated in EPCR2 cells (Branch 7–10).
Gene counts were: Branch 1, n = 405; Branch 2, n = 198; Branch 3, n = 59; Branch 4, n = 54; Branch 5, n = 624; Branch 6, n = 2; Branch 7, n = 107; Branch
8, n = 844; Branch 9, n = 85; Branch 10, n = 264 (see Table S1 for gene lists). The genes for each cluster were used as input into Ingenuity IPA to identify
pathway annotations or representation of gene signatures (see Table S2).
doi:10.1371/journal.pone.0061071.g001
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cells reduces lung metastasis [18], indicating a role for EPCR in
tumor cell survival in vascular niches. However, we found no
differences in spontaneous lung metastasis between PyMT-
EPCRLow/Low and PyMT-EPCRLow/WT mice (Fig. S1B).
The reduced tumor growth and increased overall survival could
have been caused by functions of EPCR expressed by tumor cells
or cells of the tumor microenvironment, e.g. macrophages or
endothelial cells [14]. Analysis of hematoxylin and eosin staining
of EPCRLow/Low and EPCRLow/WT tumors revealed no differ-
ences in the overall organization of the tumor mass between
genotypes (Fig. S1C). The number of CD34+ tumor vessels did not
differ between EPCRLow/Low and EPCRLow/WT tumors, although
quantification of CD34+ areas indicated a somewhat increased
vessel size in EPCRLow/Low tumors (Fig. S1D, E). In addition, the
density of F4/80+ macrophages in late stage tumors was not
different between groups (Fig. S1F). In order to directly evaluate
potential contributions of EPCR in the host compartment to
tumor growth, we transplanted PyMT tumor cells derived from
WT mice into either EPCRLow/Low or control heterozygous
EPCRLow/WT mice. In the depicted (Fig. 2B) and an independent
experiment, PyMT WT tumors grew at the same rate in both
hosts, indicating that reduced EPCR expression by the tumor cells
was responsible for the observed attenuated tumor growth in the
model of spontaneous tumor development.
Figure 2. EPCR supports tumor growth in a murine model of spontaneous and carcinoma breast cancer model. A Cohorts of PyMT
mice expressing very low levels of EPCR (EPCRLow/Low, n = 26) and control mice (EPCRlow/WT, n = 29) were followed weekly for appearance of palpable
tumors (upper panel) and tumor growth. Tumor appearance was not different between cohorts, but cumulative tumor volumes were reduced in
EPCRLow/Low versus EPCRlow/WT mice (middle panel, *p,0.05, Mann-Whitney, mean6SEM). EPCRlow/WT heterozygous control mice are eliminated from
the cohort due to large tumor sizes earlier, resulting in significantly increased survival for EPCRLow/Low mice (lower panel, ***p,0.001 Log Rank Test).
Note that EPCRlow/WT mice had similar tumor sizes as C57BL/6 mice followed at the same time in the same facility, indicating that there was no gene
dose effect in heterozygous mice. B PyMT-WT cells (26106 cells/mouse) were injected into the mammary gland of EPCRlow/WT or EPCRLow/Low mice
and a typical experimental outcome for tumor growth is shown (no difference between groups, n = 8 mice/group; mean6SD; confirmed in an
independent experiment). C Western blotting for EPCR and TF of cell lysates from PyMT-EPCRflox/flox cells treated twice with 1000 particles/cell (ppc)
of Ad5 control or Ad5 cre recombinase D. Cells depicted in C (46106 cells/mouse) were implanted into the mammary fat pad of heterozygous
EPCRlow/WT female mice (** p,0.005, T-test, n = 7 mice/group; mean6SD). Final tumor weights (*** p,0.001, T-test; mean6SD). E An independently
established PyMT-EPCRflox/flox line was selected by passage through the mammary fat pad (mfp), treated with Ad5 control or Ad5 Cre virus, and
injected at a dose of 16105 cells/mouse into the mfp of C57BL/6 female mice for tumor growth monitoring (delayed tumor appearance * p,0.05,
Log-rank Test, and reduced tumor weights, **p,0.005, T-test, n = 8; mean6SD).
doi:10.1371/journal.pone.0061071.g002
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EPCR expression by PyMT breast cancer cells supports
tumor growth
In order to directly address the role of tumor cell-expressed
EPCR, we developed a novel genetic model that enabled the
generation of matched pairs of EPCR-expressing and deficient cell
populations. We isolated tumor cells from PyMT-EPCRflox/flox
mice and treated the established lines with adenovirus (Ad5)
control or Ad5 encoding cre recombinase. Transduction of cre
recombinase efficiently deleted EPCR without reducing expression
of other surface receptors, including TF (Fig. 2C). Deletion of
EPCR did not influence proliferation under standard tissue culture
conditions or in mammospheres (Figs. S2A, B). With two
independent tumor isolates, deletion of EPCR significantly
reduced orthotopic tumor growth in the mammary fat pad
(Fig. 2D). We confirmed by Western blotting that EPCR remained
deleted in the tumors in vivo (Fig. S2C), supporting the conclusion
that attenuated tumor growth was caused by reduced EPCR
expression. H&E stained tumors showed no differences in tumor
architecture (Fig. S2D)
In order to assure optimal tumor growth properties and
minimize selection artifacts of the initial tumor cell isolation, we
passaged one line through the mammary fat pad of C57BL/6J
mice followed by re-isolation. EPCR was again deleted using cre
recombinase-expressing adenovirus versus control. We implanted
into the mammary fat pad a 10-fold lower cell dose than in the
previous experiment. EPCR deletion significantly delayed the
appearance of tumors (median 46 days for Ad5 cre-treated versus
42 days for Ad5 controls) and reduced final tumor weights
(Fig. 2E). The delayed appearance of EPCR2 transplanted tumors
provided initial evidence that EPCR supported survival or
expansion of tumor-initiating populations of fully transformed
cancer cells in the orthotopic tumor microenvironment.
EPCR+ cells of the MDA-MB-231 mfp line have stem cell
like properties
EPCR was expressed by a distinct subpopulation in MDA-MB-
231 mfp cells (Fig. 1). We first asked whether EPCR marked the
mammosphere-forming, stem cell-like subpopulations of the
MDA-MB-231 mfp line, as previously shown for other breast
cancer lines [30,35]. Within 10 days, EPCR+ cells formed
abundant mammospheres, yielding .20-fold the number of cells
in comparison to cultures initiated with the same number of
FACS-isolated EPCR2 cells (Fig. 3A). MDA-MB-231 mfp cells
also contained a larger subpopulation of EPCR+ cells as compared
to the parental line (3–4% for MDA-MB-231 vs .25% for MDA-
MB-231 mfp), and produced more mammospheres, when seeded
at identical cell densities, suggesting that expansion of the EPCR+
cells correlated with the more aggressive phenotype of MDA-MB-
231 mfp cells. EPCR+ cells also displayed ALDH1 activity
(Fig. 3B), considered another marker for cancer stem cell-like
populations and poor prognosis [29].
Next we tested the ability of EPCR+ cells to form tumors in vivo.
Viability of sorted EPCR+ and EPCR2 was similar and expansion
of sorted single cells in vitro yielded comparable numbers of
colonies for both populations (EPCR+ 33/500 sorted cells,
EPCR2 27/500 sorted cells). Analysis of randomly selected
outgrow colonies showed that 11/11 EPCR+ sorted cells expressed
EPCR. Conversely, 2/10 colonies derived from EPCR2 sorted
cells expressed EPCR, indicating inefficient EPCR staining of a
minor subpopulation during the sorting procedure or, potentially,
conversion to the EPCR+ population under the tissue culture
conditions. Freshly FACS-sorted cells were injected embedded in
matrigel into the mammary fat pad of CB17/SCID mice. Injected
EPCR+ cells formed significantly more tumors at lower numbers of
injected tumor cells and average tumor sizes were larger in
comparison to tumors developing from injected EPCR2 cells in 2
independent experiments (Table 1).
We recovered tumor cells by paramagnetic bead selection for
human integrin b1 of dispersed tumors. Analysis for TF and
EPCR expression showed that irrespective of the implanted tumor
cell population, the majority of outgrown tumor cells presented
with a EPCR2/TFhigh phenotype (Fig. 3C), indicating a
conversion from EPCR+ to EPCR2 cells in the tumor microen-
vironment in vivo. Tumor cell populations recovered by outgrow of
minced tumor and stained for EPCR and TF using our standard
protocol confirmed that cells constituting the majority of the tumor
mass were EPCR– and excluded potential problems in receptor
detection on freshly isolated tumor cells (data not shown). Thus,
EPCR expression was associated with improved tumor take,
raising the question whether EPCR directly contributed to breast
tumor initiation capacity in the orthotopic microenvironment.
Blocking EPCR attenuates tumor initiation and growth
Prompted by the microarray data (Fig. 1D) demonstrating
preferential expression of certain integrins by EPCR+ cells, we
investigated integrin expression and function further. It is known
from skin carcinoma that additional surface markers can separate
a subpopulation with distinct tumor-initiating properties in the
stem cell pool defined by high level expression of integrin a6 [45].
Whereas both EPCR+ and EPCR2 populations expressed
comparable levels of integrin a6, EPCR2 cells expressed integrin
b4 that forms the epithelial laminin receptor a6b4 (Fig. 4A). In
addition, EPCR+ cells expressed integrin a4 that is involved in
hematopoietic stem cell retention in the bone marrow [44].
Considering the distinct integrin profiles of EPCR+ and EPCR2
cells, we therefore asked whether ligation of defined integrins
could uncover functions of EPCR in cell survival and/or
proliferation in vitro. We used a pair of inhibitory (aEPCR-1535)
[21,49] and non-blocking (aEPCR-1500) [50] antibodies as well as
an IgG1 isotype-matched control. These antibodies had no effect
on mammosphere growth of unsorted cells (Fig. S3A), excluding
non-specific general toxicity. FACS sorted cells were seeded on
plates coated with the CS-1 fibronectin fragment that specifically
ligates integrin a4, supernatant from 805 G cells that is enriched
in the integrin a6 ligand laminin 5. After 48 hours of culture in the
presence of antibodies, the inhibitory aEPCR-1535 significantly
reduced numbers of viable cells as determined by the MTT assay
when EPCR+ cells were plated on CS-1 and 805 G matrix, but the
antibody had no significant inhibitory effect when added to
EPCR2 cells (Fig. 4B). These data indicated that engagement of
subpopulation-specific integrins expressed by EPCR+ cells en-
hanced proliferation or survival in dependence on EPCR
interactions with an unknown or one or more of the coagulation
protease ligands present in the serum-containing culture medium.
We next addressed whether blocking EPCR ligand interaction
had an effect on the tumor-initiating capacity of EPCR+ cells. We
injected 10,000 FACS-isolated EPCR+ cells admixed with matrigel
containing the various antibodies. Whereas .80% of the mice
injected with cells in the presence of control IgG or the non-
inhibitory aEPCR-1500 developed tumors, tumor-take was
observed in only 50% of the animals receiving cells together with
the inhibitory aEPCR-1535 (Fig. 4C). The significantly reduced
tumor initiation was also reflected in smaller tumor sizes at
sacrifice in the group of mice receiving EPCR+ cells together with
inhibitory antibody.
We next asked whether blocking EPCR also reduced tumor
growth when the cancer stem cell-like subpopulation was
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Figure 3. EPCR+ MDA-MB-231 mfp cells have stem cell-like properties. A EPCR+ and EPCR2 subpopulations isolated based on the gates in
Fig. 1A were seeded at 104 cells/well and grown in mammosphere medium for 10 days. Growth was quantified by cell counting B MDA-MB-231 mfp
cells were sorted based on EPCR. Sorted EPCR+ and EPCR2 cells, as well as parental cells were cultured for 3 days, harvested and stained with the
ALDH kit with DEAB addition as a specificity control, and analyzed by FACS. EPCR+ cells had higher ALDH activity than EPCR2 or parental cells. At the
time of analysis, the parental populations had 8% EPCR+ cells. The experiment was repeated with the same outcome. C Tumor cells were isolated
from freshly harvested tumors and immediately analyzed by FACS for TF and EPCR. A representative FACS profile and quantification for 12 EPCR+ cell-
derived tumors and 4 EPCR2 cell-derived tumors are shown (mean6SD).
doi:10.1371/journal.pone.0061071.g003
Table 1. Tumor-initiating capacity of EPCR+ and EPCR2 cells in the mfp.
Injection of EPCR+ cells
Injection of EPCR2
cells
Cell number Tumor take Volume (mm3) Weight (g) Tumor take
Volume
(mm3) Weight (g)
Experiment 1 50 000 4/4 8236205 160.17 2/4 423662 0.460.2
3000 4/4 7566474 0.960.4 0/4
1000 3/4 3526203 0.860.4 0/4
Experiment 2 10 000 4/4 5826320 0.860.4 0/4
5 000 4/4 10736441 1.460.5 J 256 0.3
3000 3/4 930680 1.260.3 J 429 0.7
1000 3/4 7576223 160.3 3/4 199656 0.360.1
EPCR-expression was associated with increased tumor take (p,0.001), increased tumor volume (p,0.01), and increased tumor weight (p,0.001) in tumors developing
from the same number of injected cells (two-way ANOVA test).
doi:10.1371/journal.pone.0061071.t001
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inoculated together with EPCR2 cells in the absence of matrigel.
Co-injection of MDA-MB-231 mfp cells with aEPCR-1535 into
the mammary gland of SCID mice resulted in a significant
decrease in tumor growth and final tumor weights relative to
control IgG (Fig. 5A). H&E staining of treated tumors showed
similar tumor architecture between the groups (Fig. S3B). In order
to rule out non-specific effects of co-injecting the antibodies with
the tumor cells, we first implanted MDA-MB-231 mfp cells into
the mammary glands of CB17/SCID mice and 4 days later began
a treatment cycle of 5 intraperitoneal injections of IgG1 control,
inhibitory aEPCR-1535, or non-inhibitory aEPCR-1500. We
confirmed by FACS analysis of CHO cells overexpressing mouse
EPCR that the employed mouse anti-human EPCR antibodies
lacked cross-reactivity with mouse EPCR, assuring that the
observed in vivo effects were due to specific blockade of human
tumor cell expressing EPCR (data not shown). Treatment with the
function-blocking aEPCR-1535 resulted in significantly slower
tumor growth relative to control and non-inhibitory antibody and
Figure 4. Blocking EPCR alters proliferation in vitro and tumor take of MDA-MB-231 mfp cells in vivo. A Sorted cells were stained for
integrin subunits a4, a6, b1 and b4 and analyzed by FACS. EPCR+ cells are a4b1 positive whereas EPCR2 cells are a4 negative, but express b1.
Conversely, EPCR2 cells expressed a6b4, and EPCR+ expressed a6 but not b4 integrin. B FACS-isolated EPCR+ or EPCR2 cells were seeded in 48-well
plates coated with CS-1 (5 mg/ml), or serum-free 805 G cell supernatant diluted 1:2 with DMEM, and cultured in the presence of 100 mg/ml control
IgG, aEPCR-1500, or aEPCR-1535 for 48 hours. Cell numbers were quantified by MTT assay (different between control IgG and aEPCR-1535, *p,0.05
ANOVA, followed by Bonferroni test, n = 3, mean6SD). C MDA-MB-231 mfp FACS-isolated EPCR+ cells (104/mouse) were injected into the mammary
fat pad in matrigel containing 0.5 mg of either control IgG, non-blocking aEPCR-1500 or blocking aEPCR-1535. The blocking antibody significantly
reduced tumor take (** p,0.005, Log-rank Test, n = 7 for IgG and aEPCR-1500, n = 8 for aEPCR-1535) and final tumor sizes (** p,0.005 versus control
IgG, ANOVA with Bonferroni post test, mean6SD).
doi:10.1371/journal.pone.0061071.g004
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yielded significantly smaller final tumor sizes and weights versus
control at sacrifice (Fig. 5B). Histological analysis of tumors from
treated mice showed no difference in tumor architecture (Fig.
S3C).
These data in murine and human breast cancer cells
concordantly showed functional roles of EPCR in orthotopic
tumor initiation and growth. The inhibition by a blocking
antibody furthermore implicated ligand interactions with this
receptor in tumor growth in the mammary fat pad. EPCR is
known to bind three coagulation proteases, i.e. PC/aPC, FVIIa,
and FX/FXa. While coagulation factor ligands for EPCR
conceivably might enter the tumor microenvironment due to the
hyper-permeability of the tumor vasculature, this pathway was
difficult to rationalize during tumor initiation by a low number of
injected cancer stem cells. We therefore returned to the PyMT
model and asked whether cells in the tumor microenvironment
expressed coagulation factors that interact with EPCR. Because
tumor cells [51] and macrophages [52] were known to synthesize
FVII, we fractionated dissociated tumor cell suspensions by
aCD11b or aCD11c paramagnetic bead selection (Fig. 6A and
B). Whereas the macrophage-depleted stromal fraction showed
high expression of TF, PAR1, PAR2, and matriptase (ST14), a
known cancer cell-expressed serine protease [53], EPCR was
expressed at similar levels by macrophages and other cells in the
tumor microenvironment. Most important, FVII was exclusively
and FX was predominantly expressed by tumor associated
macrophages. There was no detectable mRNA expression of
prothrombin, but PC was expressed at low levels in both
compartments. Genetic mouse strains with cell-type specific
deletion of these proteases are currently not available for further
analysis of relevant counter ligands for EPCR. Nevertheless, these
data support the concept that EPCR+ cancer stem cell-like
populations may be regulated by known protease ligands
ectopically synthesized by cells in the tumor microenvironment.
Figure 5. Blocking EPCR decreases tumor growth of human breast cancer cells. A MDA-MB-231 mfp cells (16106 cells/mouse) were mixed
with 1 mg control IgG or aEPCR-1535 and injected into the mammary fat pad of SCID mice. Blocking EPCR significantly reduced tumor growth and
final tumor weights (**p,0.05, T-test, mean6SD, n = 8 mice/group). B MDA-MB-231 mfp cells (16106 cells/mouse) were injected in the mammary fat
pad of SCID mice and mice were treated at days 4, 7 10, 12, and 15 by intraperitoneal injections of 1 mg of control IgG, aEPCR-1500, or aEPCR-1535.
Treatment with inhibitory aEPCR-1535 significantly reduced tumor growth and final tumor weights (ANOVA followed by Bonferroni posttest,
* p,0.05, ** p,0.005, *** p,0.001 IgG versus aEPCR-1535; # p,0.05 aEPCR-1500 versus aEPCR-1535, 1 p,0.05 IgG versus aEPCR-1500).
doi:10.1371/journal.pone.0061071.g005
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Discussion
Cancer stem cell-like subpopulations have attracted attention
because of their increased chemotherapy and radiation resistance
and their potential to be responsible for tumor relapse and
metastasis under standard therapy [33,54]. A better comprehen-
sion of cancer stem cell biology is required to develop pertinent
new cancer therapies, in particular for highly aggressive basal-like
breast cancer with poor prognosis and few therapeutic options
after relapse. Here we provide genetic evidence that EPCR, a
receptor with important roles in vascular biology and a known
stem cell marker in a variety of normal stem cell pools, has a role
in tumor progression of breast cancer. Furthermore, we show that
an inhibitory antibody to EPCR expressed by human triple
negative breast cancer cells attenuates tumor initiation and
growth, indicating that ligands for EPCR present in the tumor
microenvironment regulate these cancer stem cell-like populations.
Whereas hematopoietic development is predominantly driven
by a hierarchical organization of stem and progenitor cells,
epithelial stem cell niches frequently consist of co-existing and
inter-converting stem cell populations [31]. CD44high/CD242 and
integrin a6high phenotypes mark cancer stem cell pools and this
profile characterizes the majority of cells in our model of highly
aggressive human triple negative breast cancer. In this population,
EPCR expression defines a distinct functional subpopulation with
increased ALDH1 expression, ability to form non-adherent
mammospheres, and markedly increased tumor-initiating capac-
ity. However, the EPCR+ population was not distinguished from
EPCR- cells by established cancer stem cell signatures. Rather,
both populations expressed markers associated with cancer stem
cell-like phenotypes as well as with EMT that also characterizes
breast cancer stem cells [55,56]. Importantly, tumors initiated with
either EPCR+ or EPCR2 cells yielded mixed populations,
indicating plasticity to interconvert. This plasticity is consistent
with prior studies that demonstrated conversion of more differen-
tiated cells into basal-like breast cancer stem cells [32,57], but may
also indicate communication between the subpopulations in vivo.
Bi-directional crosstalk between the stem cell and its niche is
critical in normal survival of stem cells and their differentiation
[31]. The EPCR+ population expressed integrin a4 and a6 that
both are critically important for hematopoietic stem cell homing to
bone marrow niches [44]. Progenitors functionally contribute to
certain stem cell niches, but hematopoietic stem cell retention and
mobilization is regulated by interactions between mesenchymal
niche cells and macrophages [31]. The contributions of macro-
phages to metastasis and tumor progression are increasingly
recognized [58] and our data show that tumor-associated
macrophages are the primary source for extrahepatic synthesis
of the EPCR ligands FVII and FX in the tumor microenviron-
ment. Thus, cancer stem cell expressed EPCR may transmit cues
from the innate immune system to regulate stem cell survival,
retention, and/or differentiation.
While appropriate genetic mouse models are currently not
available to define the relevant ectopically synthesized protease
ligands for EPCR in tumor progression, continuing exploration of
these signaling events may yield novel therapeutic approaches.
Our proof of principle experiments with an inhibitory antibody to
EPCR expand the emerging evidence [34] that cancer stem cell
markers can be targeted for preclinical therapeutic benefit. While
EPCR plays important roles in regulating the host defense to
Figure 6. Expression analysis of PyMT tumor macrophages. PyMT tumors from heterozygous PyMT-EPCRLow/WT mice were dispersed and
macrophages were separated with aCD11b (A) or aCD11c (B) paramagnetic beads from tumor cells and stromal cells. Tumor macrophages were
CD11b+/CD11c+/F4/80+ by FACS and CD11c was used to assess the efficiency of selection. Expression of the indicated mRNAs was determined by RT-
PCR. Coagulation factor mRNA was normalized to a standard curve of normal mouse liver mRNA (* p,0.05, ** p,0.005 T-test, mean6SD, n= 5–8).
doi:10.1371/journal.pone.0061071.g006
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infection [59–61], there are no conclusive data to indicate that
long term blockade of EPCR or loss of EPCR [38] increases the
risk of thrombosis and would limit the application of inhibitory
antibodies to EPCR to block tumor growth.
However, the protease ligands and their proteolytic signaling
effects on the stem cell populations are similarly attractive targets
for cancer therapy. Small molecule anticoagulants targeting
specific coagulation proteases are entering the clinic for a variety
of thrombosis indications and may have unexpected therapeutic
benefit in interrupting the cancer stem cell EPCR signaling
pathways that are initiated by the extra-hepatic synthesis of
coagulation factors by tumor-associated macrophages. Identifying
EPCR’s protease ligand will be instrumental to select an optimal
anticoagulant strategy that synergizes with conventional cancer
therapy by specifically targeting cancer stem cell-like populations
as an adjuvant therapy.
Supporting Information
Figure S1 Metastasis and tumor analysis in the synge-
neic PyMT breast cancer model. A Cohorts of PyMT mice
expressing very low levels of EPCRlow/WT (n = 29) or PyMT
C57BL/6J (n = 15) were followed weekly for tumor growth.
B Lungs of PyMT EPCRLow/Low (n= 18) versus EPCRlow/WT
(n = 16) were harvested and fixed in Bouin’s solution for counting
of visible surface metastases. No significant differences in lung
metastatic burden were observed between PyMT-EPCRLow/Low
and PyMT-EPCRLow/WT control cohorts (mean shown).
C Spontaneous PyMT-EPCRLow/Low and PyMT-EPCRLow/WT
tumors were stained with H&E in order to detect potential
differences in the organization of the tumor (scale bar 50 mm).
D EPCRlow/WT and EPCRLow/Low tumors obtained at sacrifice
were stained for CD34. Vessel density and area were quantified
with the image analysis software IMARIS. Vessel size, but not
density was increased (***p,0.001, Mann-Whitney test, n = 7
tumors/genotype; mean6SD). E Representative images of CD34
staining scale bar: 30 mm. F F4/80 stained tumor sections were
counterstained with DAPI for total cell number to quantify
macrophage counts (p = 0.1; mean6SD, n= 5 tumors/genotype).
(TIF)
Figure S2 Analysis of in vitro growth of EPCR-deleted
PyMT cells and tumor histology. A. Proliferation: Cells were
plated in 48-well plate for 48 hours and viable cell numbers were
quantified by MTT assay (mean6SD, n= 3). B Mammosphere
growth: 104 PyMT EPCR-expressing or deleted cells/well were
seeded in low attachment plates and grown in mammosphere
media for 10 days. Mammosphere sizes were quantified from
images with Photoshop CS4 (mean6SD, n= 3). Concordant
results were obtained with an independent line isolated from a
separate animal. C EPCR Ad5 control or Cre tumors (100 mg)
were harvested and lysed in octylglucoside buffer (50 mM). Lysates
were analyzed for EPCR and actin by Western Blotting.
D Histology of EPCR Ad5 control or Cre tumors. Sections were
stained with H&E; representative views from three independent
animals are shown.
(TIF)
Figure S3 Effect of anti-EPCR on mammosphere growth
and tumor histology. A. MDA-MB-231 mfp cells (104/well)
were seeded in low attachment plates with 100 mg/ml control IgG,
aEPCR-1500 or aEPCR-1535 antibody in mammosphere
medium, fresh antibody was added every 3 days. Blocking EPCR
does not alter mammosphere formation (mean6SD, n= 2,) B.
H&E staining of tumors form cells mixed with control or aEPCR-
1535 antibody. C H&E stained sections of tumors from anti-
EPCR or control antibody treated mice.
(TIF)
Table S1 Gene list of differentially expressed tran-
scripts between EPCR+/TFlow and EPCR2/TFhigh sub-
populations of MDA-MB-231mfp cells.
(PDF)
Table S2 Pathway and gene signature analysis of
differentially regulated genes in EPCR+ and EPCR2
subpopulations of MDA-MB-231mfp cells.
(PDF)
Table S3 Primers used for RT-PCR analysis of gene
expression by cell fractions of murine PyMT tumors.
(PDF)
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